What is the AVIV ETF ?
AVIV ETF: Overview
The AVIV ETF is a unique financial instrument designed to provide investors with exposure to a diverse group of non-U.S. companies across various countries, market sectors, and industry groups. Unlike traditional ETFs that replicate the performance of a specific index, the AVIV ETF is actively managed by portfolio managers who continually analyze market and financial data to make strategic investment decisions. This dynamic approach allows the fund to seek out higher returns by emphasizing securities with strong profitability and value characteristics while underweighting or excluding those expected to have lower returns.
AVIV ETF: Underlying and Exposure - What Does it Track and How?
To achieve its investment objectives, the AVIV ETF seeks securities of companies with higher profitability and value characteristics. The portfolio managers use a combination of reported and estimated company financials along with market data, including shares outstanding, book value and its components, cash flows from operations, and accruals. They define "value characteristics" primarily based on the adjusted book/price ratio, though other price to fundamental ratios may also be considered. Similarly, "profitability" is mainly assessed using the adjusted cash from operations to book value ratio, but other relevant ratios are taken into account.
Furthermore, the portfolio managers consider other factors when selecting securities, such as industry classification, past performance relative to other securities, liquidity, float, and various tax, governance, or cost considerations. This rigorous selection process ensures that only securities with the desired capitalization, profitability, value, and past performance characteristics are included in the portfolio.
AVIV overlap What is the AVIV ETF ?
AVIV ETF: Benefits to Invest in this ETF
Investing in the AVIV ETF offers several benefits for discerning investors. With its active management approach, the fund aims to outperform traditional passive ETFs by capitalizing on market opportunities and making strategic buy, sell, and hold decisions based on expected returns and implementation or tax costs. By providing exposure to a diverse range of non-U.S. companies, the AVIV ETF also offers the potential for diversification, reducing the risk associated with concentrated investments in a single market or industry.
Moreover, the emphasis on securities with higher profitability and value characteristics can lead to potentially higher returns, making the AVIV ETF an attractive option for those seeking long-term capital appreciation.
AVIV ETF: Considerations Before Investing
Before investing in the AVIV ETF, it is essential for investors to consider certain factors. As an actively managed fund, the AVIV ETF involves a higher level of management fees compared to passive ETFs that replicate an index. Investors should evaluate whether the potential benefits of active management align with their investment goals and risk tolerance.
Additionally, the AVIV ETF's focus on non-U.S. companies and exposure to foreign currencies may introduce currency risk, which can impact returns for investors based in different regions. Evaluating the fund's foreign investment exposure and understanding how currency fluctuations may affect returns is crucial.
Another consideration is the fund's allocation among different countries outside the United States. Investors should assess the geographical diversification to ensure it aligns with their global investment strategy.
Conclusion:
In conclusion, the AVIV ETF presents a compelling investment opportunity for those looking to gain exposure to a diverse group of non-U.S. companies with an active management approach. Its focus on securities with higher profitability and value characteristics may offer the potential for attractive long-term returns. However, investors must carefully consider their investment objectives, risk tolerance, and currency exposure before making a decision.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The content provided here does not endorse any specific financial product, including the AVIV ETF. Investors should conduct thorough research and consider consulting with a qualified financial advisor before making investment decisions.
AVIV ETF issuer
AVIV ETF official page
AVIV quote and analysis
Discover the top holdings, correlations, and overlaps of ETFs using our visualization tool.
Our app allows you to build and track your portfolio.
To learn more about the AVIV Avantis International Large Cap Value ETF, access our dedicated page now.
FAQ
What is the AVIV ETF?
The AVIV ETF, also known as the AVIV Therapeutics ETF, is an exchange-traded fund that aims to track the performance of the AVIV Therapeutics Index. This index includes small and mid-cap stocks of biotechnology companies that have drugs in either Phase II or Phase III of the U.S. Food and Drug Administration (FDA) clinical trials.
How does the AVIV ETF select its constituents?
The AVIV ETF includes stocks listed on a U.S. stock exchange with a market capitalization ranging from $200 million to $5 billion. Constituents must have an average daily trading volume exceeding $1 million in the 90-day period before reconstitution. The companies must be able to sustain their cash burn rates for at least 24 months.
How often does the AVIV ETF rebalance its holdings?
The AVIV ETF undergoes semi-annual reconstitution on the third Fridays of June and December. Additionally, the stocks are reviewed and rebalanced on the third Friday of the last month of each calendar quarter.
What is the investment strategy of the AVIV ETF?
The AVIV ETF follows a passive management or indexing approach. It invests at least 80% of its net assets in securities that comprise the AVIV Therapeutics Index or depositary receipts based on those securities.
What type of biotechnology companies are included in the AVIV ETF?
The AVIV ETF includes small and mid-cap biotechnology companies that have drugs in either Phase II or Phase III of FDA clinical trials. These companies are focused on developing innovative therapies, and their stock performance is tied to the success of their drug development efforts.